Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company renowned for its pioneering work in allogeneic gamma delta T cell therapies, announced that Chen Schor, the company’s President and Chief Executive Officer, will participate in a fireside chat during the 45th Annual Canaccord Genuity Growth Conference. This prestigious event is scheduled to take place from August 12-14, 2025, in Boston, with Schor's segment occurring on Tuesday, August 12, at 1:30 p.m. ET.

Adicet Bio focuses on the innovative development of “off-the-shelf” gamma delta T cell treatments engineered with chimeric antigen receptors (CARs), targeting autoimmune diseases and various forms of cancer. These therapies aim to provide durable efficacy in patients, positioning Adicet at the forefront of biotechnological advancements in oncology and immunotherapy.

The live audio webcast of the fireside chat will be accessible in the Investors section of Adicet Bio's official website, allowing stakeholders and interested parties to tune in to the discussion. For those unable to attend live, an archived replay of the presentation will be available for 30 days post-event, providing an opportunity for a broader audience to engage with the insights shared.

With a robust pipeline and commitment to improving patient outcomes through innovative therapies, Adicet Bio continues to carve out a significant niche within the competitive biotech landscape. For more detailed information about the company and its advancements in cellular therapies, interested individuals are encouraged to visit Adicet Bio's website at http://www.adicetbio.com.

For any media inquiries, Anne Bowdidge from Adicet Bio can be contacted, alongside Penelope Belnap from Precision AQ for further public relations support.

Adicet Bio, Inc. (Nasdaq: ACET) presents an intriguing investment opportunity, particularly as it prepares to participate in the 45th Annual Canaccord Genuity Growth Conference. The company's focus on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer places it at the cutting edge of biotechnology, making it a noteworthy contender for investors seeking exposure to innovative therapies in the healthcare sector.

Scheduled for August 12, 2025, Chen Schor, the President and CEO, will engage in a fireside chat, providing insights into the company's advancements and future strategies. This event is crucial for investors as it will likely illuminate the company's progress with its pipeline of "off-the-shelf" therapies, engineered with chimeric antigen receptors (CARs). These developments could offer significant long-term value given the growing demand for effective immunotherapies.

As Adicet Bio continues to progress through its clinical trials, monitoring their data releases and trial results will be vital. Investors should pay attention to any partnerships or collaborations discussed during the conference that could enhance their research capabilities or expand market reach. The management's insights into regulatory milestones and potential commercialization strategies will also provide a clearer picture of the company's trajectory.

In addition to the live event, interested parties can access the audio webcast on the company’s investor relations page, ensuring that vital information is readily available for analysis. Given the high volatility often associated with clinical stage companies, it is essential for investors to approach Adicet Bio with a balanced perspective, weighing the potential rewards against the inherent risks of biotech investments. If the fireside chat reveals compelling data or strategic partnerships, it may serve as a strong catalyst for the stock, enhancing its attractiveness for both existing and prospective investors.